---
title: AI Morbidity and Mortality: A Framework for Clinical AI Failure Review
url: http://arxiv.org/abs/2609.00076v1
type: paper-summary
date: 2026-09-01
source_paper: 2026-08-31_07-41-30Z_AIMorbidityandMortality_AFrameworkforClinicalAIFai.md
generated_at: 2026-09-01 22:11
model: nvidia/nemotron-3-nano-4b
---

## Summary
The paper introduces AI Morbidity and Mortality (AI M&M), a structured blameless framework to review clinical AI failures, combining case intake, evidence preservation, investigator reconstruction, tool‑in‑loop attribution, and corrective‑action tracking. It classifies each event across four linked dimensions: Trigger, Mechanism, Clinical Pathway, Corrective Action. Using five outpatient cases, the authors show that independent reviewers reached agreement on all 20 axis‑level classifications.

## Key Takeaways
- The framework separates risk emergence into four distinct categories—Trigger, Mechanism, Clinical Pathway, and Corrective Action—to enable systematic analysis of AI failures.
- Independent clinician review achieved consensus across all 20 classification points, demonstrating the reliability of the method in real‑world settings.
- AI M&M complements existing monitoring tools by converting individual incidents into actionable institutional learning rather than replacing them.

## Context
Current clinical AI safety practices rely on aggregate model monitoring and patient safety reporting, which capture performance changes or adverse events but lack depth to explain how risk arises across interacting systems. This gap leaves institutions unable to trace the causal chain from a faulty algorithm to a patient outcome. The proposed framework addresses this limitation by providing a granular, reproducible way to reconstruct each failure.

## Implications
Practitioners can use AI M&M to improve root‑cause analysis and implement targeted corrective actions without assigning blame, fostering a culture of continuous learning. As AI adoption expands across healthcare, such frameworks become essential for regulatory compliance and patient safety innovation.

## Original Paper Reference
- **Source**: [Original Paper](http://arxiv.org/abs/2609.00076v1)
